Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles

被引:140
作者
Mladenovska, K.
Raicki, R. S.
Janevik, E. I.
Ristoski, T.
Pavlova, M. J.
Kavrakovski, Z.
Dodov, M. G.
Goracinova, K.
机构
[1] Ss Cyril & Methodious Univ, Fac Pharm, Skopje 1000, Macedonia
[2] Ss Cyril & Methodious Univ, Fac Med, Skopje 1000, Macedonia
[3] Ss Cyril & Methodious Univ, Fac Vet Med, Skopje 1000, Macedonia
关键词
chitosan-Ca-alginate microparticles; 5-aminosalicylic acid; inflammatory bowel diseases; controlled release; colon delivery;
D O I
10.1016/j.ijpharm.2007.05.028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chitosan-Ca-alginate microparticles for colon-specific delivery and controlled release of 5-ammosalicylic acid after peroral administration were prepared using spray drying method followed by ionotropic gelation/polyelectrolyte complexation. Physicochemical characterization pointed to the negatively charged particles with spherical morphology having a mean diameter less than 9 mu m. Chitosan was localized dominantly in the particle wall, while for alginate, a homogeneous distribution throughout the particles was observed. H-1 NMR, FTIR, X-ray and DSC studies indicated molecularly dispersed drug within the particles with preserved stability during microencapsulation and in simulated in vivo drug release conditions. In vitro drug release studies carried out in simulated in vivo conditions in respect to pH, enzymatic and salt content confirmed the potential of the particles to release the drug in a controlled manner. The diffusional exponents according to the general exponential release equation indicated anomalous (non-Fickian) transport in 5-ASA release controlled by a polymer relaxation, erosion and degradation. Biodistribution studies of [I-131]-5-ASA loaded chitosan-Ca-alginate microparticles, carried out within 2 days after peroral administration to Wistar male rats in which TNBS colitis was induced, confirmed the dominant localization of 5-ASA in the colon with low systemic bioavailability. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:124 / 136
页数:13
相关论文
共 57 条
[1]  
Acartürk F, 1999, J MICROENCAPSUL, V16, P291
[2]  
Bantel H, 2000, AM J GASTROENTEROL, V95, P3452
[3]   Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine [J].
Bernkop-Schnürch, A ;
Kast, CE ;
Richter, MF .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (03) :277-285
[4]   Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid [J].
Bernstein, CN ;
Eaden, J ;
Steinhart, AH ;
Munkholm, P ;
Gordon, PH .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (05) :356-361
[5]   Prolonged-release mesalazine - A review of its therapeutic potential in ulcerative colitis and Crohn's disease [J].
Clemett, D ;
Markham, A .
DRUGS, 2000, 59 (04) :929-956
[6]   Chitosan-alginate microparticles as a protein carrier [J].
Coppi, G ;
Iannuccelli, V ;
Leo, E ;
Bernabei, MT ;
Cameroni, R .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (05) :393-400
[7]  
D'Acquisto Fulvio, 2002, Mol Interv, V2, P22, DOI 10.1124/mi.2.1.22
[8]  
De Jaeghere F, 2001, AAPS PHARMSCI, V3, part. no.
[9]   Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease [J].
Ewe, K ;
Schwartz, S ;
Petersen, S ;
Press, AG .
DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (07) :1434-1439
[10]   Preparation and characterization of Ca-alginate microspheres by a new emulsification method [J].
Fundueanu, G ;
Esposito, E ;
Mihai, D ;
Carpov, A ;
Desbrieres, J ;
Rinaudo, M ;
Nastruzzi, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 170 (01) :11-21